The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 requires federal agencies to include reasonable pricing clauses in all research grants and contracts involving biomedical products. Under this provision, U.S. residents cannot be charged more than the median price found in Canada and six other high-income OECD countries for any drug, device, or therapy developed with federal support. The Secretary of Health and Human Services is authorized to establish additional regulations, such as mechanisms to lower prices when revenues exceed targets or costs per health benefit are too high, while retaining the ability to waive these obligations if doing so serves the public interest. To ensure accountability, manufacturers must report clinical trial costs, government subsidies, and annual revenues by county, with all data made publicly available.
The Veterans Medicare Premium Transparency Act requires Medicare to clearly explain how a veteran's enrollment in the Department of Veterans Affairs patient enrollment system affects their monthly insurance premiums. Under this bill, annual notices sent to Medicare beneficiaries will explicitly state that time spent in the VA system counts toward premium calculations and qualifies as valid prescription drug coverage. Additionally, the Secretary of Health and Human Services must post this explanation on the Medicare website and submit a report to Congress within 180 days detailing the updates and estimating how many veterans were previously paying higher premiums due to this lack of clarity.
This resolution expresses support for designating the first week of August as National Community Health Center Week to honor the contributions of these facilities. It encourages all Americans to visit their local health centers during this time to celebrate the partnership between these organizations and the communities they serve. The bill highlights how community health centers provide affordable, comprehensive care to millions of people, particularly in rural and underserved areas, while integrating services like dental care, behavioral health, and pharmacy support. By recognizing these centers, the resolution aims to raise awareness of their role in improving public health outcomes and supporting local economies.
This bill modifies the Public Health Service Act to simplify the process for reviewing biosimilar drugs, which are generic versions of existing biologic medicines. By removing a specific requirement and renumbering a related clause, the legislation aims to reduce regulatory hurdles for manufacturers seeking approval for these products. The change directly impacts pharmaceutical companies and the FDA, potentially allowing for a more efficient evaluation of biosimilars without altering the fundamental safety standards.
This bill requires health insurance policies in Pennsylvania to cover at least two epinephrine delivery systems, such as EpiPens, for an annual maximum cost of $35 regardless of deductibles or copayments. It applies to standard medical insurance plans but excludes limited coverage types like dental-only or accident policies. Additionally, the state Insurance Department must investigate manufacturer pricing practices and submit a public report with recommendations to control costs within one year. Insurance companies are also permitted to offer lower out-of-pocket costs than the $35 cap if they choose.
This bill updates Michigan's requirements for pharmacists and pharmacy technicians to renew their professional licenses. It mandates that pharmacists complete at least 30 hours of approved continuing education or pass a proficiency exam over a two-year period, while pharmacy technicians must complete at least 20 hours. A key provision requires that a portion of this training specifically covers pain and symptom management. Additionally, the bill allows licensees to fulfill all their continuing education hours through online or electronic courses, provided these programs meet state-approved standards.
This bill establishes a minimum reimbursement standard for pharmacies that are not classified as critical access care facilities, requiring Medicaid managed care organizations to pay at least the same rates as the traditional fee-for-service program. The law mandates that these payments cover both the professional dispensing fee and the acquisition cost of the medication, regardless of whether the managed care organization pays the pharmacy directly or uses a third-party pharmacy benefit manager. Additionally, the bill directs the state Department of Healthcare Finance to implement various cost-control measures, such as limiting the number of prescriptions for certain drugs within a 30-day period and requiring prior approval for specific high-cost medications.
The Modernizing Opioid Treatment Access Act 2.0 of 2026 allows specific addiction medicine specialists to prescribe methadone for opioid use disorder to be dispensed directly through pharmacies, rather than requiring patients to attend traditional treatment clinics. This change permits these qualified doctors to use telemedicine for patient care and requires that the methadone be in a liquid or dispersible tablet form. While the bill maintains existing clinic-based treatment options, it streamlines access by removing the need for pharmacies to obtain separate registrations to dispense the medication. The law also mandates that patients sign informed consent forms explaining how privacy rules differ between clinic and pharmacy settings, and it requires the Drug Enforcement Administration to report on the program's progress to Congress every year.
This bill requires hospitals, laboratories, imaging centers, and ambulatory surgical centers to publicly post detailed price lists for their services, including standard charges, negotiated rates, and discounted cash prices, starting in 2027. It also mandates that private health insurance plans provide consumers with cost-sharing estimates and publish quarterly data on payment rates to doctors and pharmacies beginning in 2029. Additionally, the legislation requires Medicare Advantage and prescription drug plan sponsors to report ownership details for providers and pharmacies they control, while establishing civil penalties for entities that fail to comply with these transparency rules.